Chemotherapy of multiple myeloma: Melphalan-40 years old and still going strong

Biology of Blood and Marrow Transplantation

Volumn 9, Issue 1, 2003, Pages 2-3

  Bergsagel, P Leif ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; ANTINEOPLASTIC AGENT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; META ANALYSIS; MULTIPLE MYELOMA; NOTE; PATHOPHYSIOLOGY; SYSTEMATIC REVIEW; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MULTIPLE MYELOMA;

EID: 0141834982     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1053/bbmt.2003.50001     Document Type: Article

References (11)

1. Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep. 1962;21:87.
2. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992;10:334-342.
3. Hahn T, Wingard JR, Anderson KC, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003;9:4-37.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
5. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95:7-11.
6. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566-1571.
7. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579-1583.
8. Fonseca R, Harrington D, Blood EA, Greipp PR. A molecular classification of multiple myeloma based on cytogenetic abnormalities detected by interphase FISH, is powerful in identifying discrete groups of patients with dissimilar prognosis. Blood. 2001;98:3059a.
9. Trudel S, Ely S, Farooqi Y, et al. Rational therapy targeting the initial genetic event in multiple myeloma: FGFR3 as a drug target in t(4;14)MM. Blood. 2002;100:396a.
10. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
11. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.